WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: TD Cowen 45th Annual Healthcare Conference in Boston, MA on March 5 at 9:10 a.m. ET;Leerink Partners Global Biopharma Conference in Miami, FL on March 11 at 8:00 a.m. ET;Je ...

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this lin ...

Kymera Therapeutics (KYMR) Conference Call Summary Company Overview - **Company**: Kymera Therapeutics (KYMR) - **Focus**: Targeted protein degradation to develop new medicines, particularly in the field of immunology and autoimmune diseases [4][5] Strategic Priorities - **Immunology Strategy**: The company aims to advance and expand its autoimmune disease target portfolio, leveraging targeted protein degradation to create oral drugs with biologics-like efficacy [3][4][5] - **Current Programs**: - IREC4 in Phase 2b with NHS and AD in collaboration with Sanofi - STAT6 agent in Phase 1 for TH2 driven inflammation [6][9] - Upcoming program expected to enter the clinic in early 2026 [7] Market Opportunity - **Patient Access**: Out of approximately 160 million patients with common immune inflammatory diseases, only 5 million (3%) currently have access to advanced systemic therapy. Kymera aims to change this by providing oral drugs [9] - **Potential Value**: The company estimates the opportunity could represent hundreds of billions of dollars [9] Product Development Insights - **KT-621 (STAT6 Degrader)**: - Designed to replicate the effects of IL-4 and IL-13 antibodies like dupilumab, with a knockdown efficacy of over 90% [10][11] - Preclinical data suggests it may be more potent than dupilumab, with an IC50 in the low picomolar range [11] - Strong human genetics support the safety and efficacy of targeting STAT6 [12] Clinical Development Strategy - **Phase 1b Study**: Focused on safety and degradation in healthy volunteers, with plans to establish a biomarker profile in atopic dermatitis patients [21][24] - **Future Studies**: Plans to run parallel Phase 2b studies in asthma and atopic dermatitis, with the aim of establishing a robust safety and efficacy profile [34][36] Financial Position - **Capitalization**: The company has $850 million as of December, which is expected to fund operations through mid-2027, allowing for multiple Phase 2b studies across its pipeline [37] Partnership and Collaboration - **Sanofi Partnership**: KT-474 is being developed in collaboration with Sanofi, which is responsible for operational and financial aspects of the ongoing studies [41][42] - **Future Opportunities**: The company is exploring additional indications beyond HS and AD, with a focus on derisked opportunities [43] Additional Programs - **KT-295 (TIG2 Inhibitor)**: Expected to enter Phase 1 study, similar in approach to the STAT6 program, focusing on degradation, safety, and pathway impact [44] Conclusion - Kymera Therapeutics is positioned to leverage its innovative approach in targeted protein degradation to address significant unmet needs in the autoimmune disease market, with a strong pipeline and strategic partnerships to support its development efforts [9][37]

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; andOppenheimer 35th Annual Healthcare Life Scienc ...

Core Insights - Kymera Therapeutics, Inc. (KYMR) announced its business goals for 2025, focusing on its immunology pipeline, leading to an 8% increase in stock price and a 47.2% rise over the past year compared to a 16% decline in the industry [1] Pipeline Updates - Kymera is developing KT-621, a first-in-class oral degrader of STAT6, showing dupilumab-like activity and strong safety data in preclinical models [2] - Recruitment is ongoing for a phase I study of KT-621, which has potential applications in various Th2 diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease [3] - Kymera plans to complete the phase I study and report data in Q2 2025, with a phase lb study in atopic dermatitis also set for Q2 2025 and a phase IIb study planned for Q4 2025 [4] Additional Candidates - Kymera is evaluating KT-295, a first-in-class oral degrader of TYK2, with plans to file an investigational new drug application and initiate a phase I study in Q2 2025, expecting data in Q4 2025 [5] - KT-474 (SAR444656), an IRAK4 degrader, is in development for immune-inflammatory diseases, with Sanofi planning to expand ongoing mid-stage studies toward pivotal studies following positive preliminary data [6][7] - Kymera and Sanofi aim to advance KT-474 in phase IIb studies for hidradenitis suppurativa and atopic dermatitis, with primary completion expected in 2026 [8] Future Developments - Kymera plans to announce a new immunology program targeting an undrugged transcription factor in H1 2025, with clinical testing expected in early 2026 [10] - The company decided not to continue developing KT-333 and KT-253 beyond phase I due to a strategic focus on its immunology pipeline [10] Financial Position - As of December 31, 2024, Kymera had an estimated $850 million in cash, sufficient to fund operations into mid-2027 [11]

Kymera Therapeutics, Inc. (KYMR) shares rallied 7.8% in the last trading session to close at $40.12. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.6% loss over the past four weeks.Shares gained as investors were impressed by the pipeline updates provided by the company at the J.P. Morgan Annual Healthcare Conference. Kymera has a sound cash position and ended 2024 with an estimated cash of $850 million, ...

Exhibit 99.2 January 2025 J.P. Morgan Healthcare Conference Nello Mainolfi, Ph.D., Founder, President and CEO ,KYMERA This presentation contains forward-looking statements within the meanine of the Private Securities Litiation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, inplied and express statements about our stratesy, business plans and digictives for the inclinerines for the preclinical and cl regarding timing, success and data announcements of ...

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively KT-295 (TYK2) to advance into Phase 1 testing in 2Q25 with data expected in late 2025 KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD ongoing, with completion expect ...

Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][3] - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, where CEO Nello Mainolfi will discuss the company's progress and milestones for 2025 [1] Company Overview - Kymera is pioneering targeted protein degradation (TPD) to create therapies for health issues that conventional treatments cannot effectively address [3] - The company has advanced its first degrader into clinical trials for immunological diseases and aims to build a leading pipeline of oral small molecule degraders [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Presentation Details - A live webcast of the presentation and Q&A session will be available on the company's website, with a replay archived after the event [2]

Kymera Therapeutics, Inc. (KYMR) reported a loss of 82 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 83 cents. In the year-ago quarter, Kymera reported a loss of 90 cents per share.Collaboration revenues totaled $3.7 million, which missed the Zacks Consensus Estimate of $9 million. The reported figure increased 20.8% from the year-ago level.Collaboration revenues in the third quarter were mostly earned due to the company’s association with bigwig Sanof ...